239 related articles for article (PubMed ID: 22871634)
21. Scintillation proximity assays for mechanistic and pharmacological analyses of HIV-1 integration.
Grobler JA; Stillmock KA; Hazuda DJ
Methods; 2009 Apr; 47(4):249-53. PubMed ID: 19285556
[TBL] [Abstract][Full Text] [Related]
22. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.
Sierra-Aragón S; Walter H
Intervirology; 2012; 55(2):84-97. PubMed ID: 22286875
[TBL] [Abstract][Full Text] [Related]
23. New first and second generation inhibitors of human immunodeficiency virus-1 integrase.
Pendri A; Meanwell NA; Peese KM; Walker MA
Expert Opin Ther Pat; 2011 Aug; 21(8):1173-89. PubMed ID: 21599420
[TBL] [Abstract][Full Text] [Related]
24. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C
Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922
[TBL] [Abstract][Full Text] [Related]
25. Rational design of 2-pyrrolinones as inhibitors of HIV-1 integrase.
Ma K; Wang P; Fu W; Wan X; Zhou L; Chu Y; Ye D
Bioorg Med Chem Lett; 2011 Nov; 21(22):6724-7. PubMed ID: 21996518
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 integrase inhibitors: update and perspectives.
Semenova EA; Marchand C; Pommier Y
Adv Pharmacol; 2008; 56():199-228. PubMed ID: 18086413
[No Abstract] [Full Text] [Related]
27. 6-aryl-2,4-dioxo-5-hexenoic acids, novel integrase inhibitors active against HIV-1 multiplication in cell-based assays.
Costi R; Di Santo R; Artico M; Roux A; Ragno R; Massa S; Tramontano E; La Colla M; Loddo R; Marongiu ME; Pani A; La Colla P
Bioorg Med Chem Lett; 2004 Apr; 14(7):1745-9. PubMed ID: 15026063
[TBL] [Abstract][Full Text] [Related]
28. Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon.
Aghokeng AF; Kouanfack C; Peeters M; Mpoudi-Ngole E; Delaporte E
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):1-3. PubMed ID: 22889147
[No Abstract] [Full Text] [Related]
29. Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load.
Papendorp SG; van den Berk GE
AIDS; 2009 Mar; 23(6):739. PubMed ID: 19279447
[No Abstract] [Full Text] [Related]
30. Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Parrotta L; Perno CF; Svicher V
Drug Resist Updat; 2011 Jun; 14(3):141-9. PubMed ID: 21295512
[TBL] [Abstract][Full Text] [Related]
31. [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].
Delaugerre C
Med Mal Infect; 2010 Sep; 40 Suppl 1():S1-10. PubMed ID: 20800182
[TBL] [Abstract][Full Text] [Related]
32. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.
McColl DJ; Chen X
Antiviral Res; 2010 Jan; 85(1):101-18. PubMed ID: 19925830
[TBL] [Abstract][Full Text] [Related]
33. Clinical management of HIV-1 resistance.
Paredes R; Clotet B
Antiviral Res; 2010 Jan; 85(1):245-65. PubMed ID: 19808056
[TBL] [Abstract][Full Text] [Related]
34. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
Summa V; Petrocchi A; Bonelli F; Crescenzi B; Donghi M; Ferrara M; Fiore F; Gardelli C; Gonzalez Paz O; Hazuda DJ; Jones P; Kinzel O; Laufer R; Monteagudo E; Muraglia E; Nizi E; Orvieto F; Pace P; Pescatore G; Scarpelli R; Stillmock K; Witmer MV; Rowley M
J Med Chem; 2008 Sep; 51(18):5843-55. PubMed ID: 18763751
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 integrase inhibitors: 2005-2006 update.
Dayam R; Gundla R; Al-Mawsawi LQ; Neamati N
Med Res Rev; 2008 Jan; 28(1):118-54. PubMed ID: 17979144
[TBL] [Abstract][Full Text] [Related]
36. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
[TBL] [Abstract][Full Text] [Related]
37. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells.
Mekouar K; Mouscadet JF; Desmaële D; Subra F; Leh H; Savouré D; Auclair C; d'Angelo J
J Med Chem; 1998 Jul; 41(15):2846-57. PubMed ID: 9667973
[TBL] [Abstract][Full Text] [Related]
38. Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection.
Anker M; Corales RB
Expert Opin Investig Drugs; 2008 Jan; 17(1):97-103. PubMed ID: 18095922
[TBL] [Abstract][Full Text] [Related]
39. Integrase strand transfer inhibitors in the management of HIV-positive individuals.
Mesplède T; Quashie PK; Zanichelli V; Wainberg MA
Ann Med; 2014 May; 46(3):123-9. PubMed ID: 24579911
[TBL] [Abstract][Full Text] [Related]
40. Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy.
Young B; Fransen S; Greenberg KS; Thomas A; Martens S; St Clair M; Petropoulos CJ; Ha B
Antivir Ther; 2011; 16(2):253-6. PubMed ID: 21447875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
